---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-061150"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2026-05-14T20:06:06+00:00"
generated_at: "2026-05-14T21:01:17.684079+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Elutia reports Q1 net loss $7.5M; NXT-41x on track for clearance in H1 2027

## Summary
- Net loss from continuing ops $7.9M vs $1.9M loss in Q1 2025; net loss $7.5M vs $3.9M.
- Cash & escrow $36.5M; NXT-41 510(k) clearance expected Q4 2026, NXT-41x clearance H1 2027.
- Net sales $3.1M (+6% YoY); SimpliDerm $2.1M, Cardiovascular $1.0M.
- Adjusted gross margin 66.5% vs 55.9% YoY; new automated mfg supports >80% gross margin target.
- Exploring SimpliDerm divestiture; received inbound inquiries for Cardiovascular product line.

## SEC filing metadata
- accession: 0001104659-26-061150
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2026-05-14T20:06:06+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465926061150/0001104659-26-061150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465926061150/elut-20260514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-061150
- JSON: https://secwatch.observer/filing/0001104659-26-061150.json
- Plain text: https://secwatch.observer/filing/0001104659-26-061150.txt

## Key facts
- Earnings Releases
  ELUTIA INC. reported the first quarter ended March 31, 2026 results: revenue $3.1 million, net income $7.5 million.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $3.1 million
  - Net income: $7.5 million
  - Result: reported results
  source text: results discussed below reflect continuing operations. For the three-month period ended March 31, 2026, as compared to the same period of 2025: ● Overall net sales were $3.1 million, compared to $3.0 million, an increase of 6%. ● Net sales of SimpliDerm were $2.1 million, compared to $2.6 million. ● Net sales of Cardiovascular products were $1.0 million,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708527/000110465926061150/0001104659-26-061150-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.